<?xml version="1.0" encoding="UTF-8"?>
<p id="par0175">These results are comparable to another Chinese open-label, randomized, controlled trial that included 150 hospitalized COVID-19 patients. HCQ dosage in this study was 1, 200 mg daily for 3 days with a maintenance dose of 800 mg daily for 2 or 3 weeks depending on illness severity. No difference regarding negative viral conversion was observed between the HCQ and the standard of care group, but significant clinical improvement was noticed in the HCQ group [
 <xref rid="bib0300" ref-type="bibr">60</xref>].
</p>
